Cabergoline Targets Multiple Pathways to Inhibit PRL Secretion and Increases Stromal Fibrosis

By sjmartinez • May 24, 2024

Zhang D, Hugo W, Bergsneider M, Wang MB, Kim W, Han K, Vinters HV, Heaney AP. Cabergoline Targets Multiple Pathways to Inhibit PRL Secretion and Increases Stromal Fibrosis. Eur J Endocrinol. 2024 May 23:lvae055. doi: 10.1093/ejendo/lvae055. Epub ahead of print. PMID: 38781434.

Tags: Cabergoline, Dermatology, Endocrinology, Pituitary tumor, Prolactinomas, Publications, ScRNAseq, tumor microenvironment

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, Gottlieb AB, Zeng X, Thaçi D, Kishimoto M, Schulze-Koops H, Kivitz A, Dokoupilová[...]

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]